Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | October 01, 2026 | October 07, 2026 |
| Galera Therapeutics, Inc.GRTX · Entity 15899 | Chief Operating Officer | February 25, 2023 | March 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date October 01, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 14,328 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Disposition to issuer · Disposed 17,948 · Balance 14,328 F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.
Galera Therapeutics, Inc.
Report date February 25, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2033-02-24 | Direct | 135,000 |
Reported balance
After 2023-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-25 · Grant · Acquired 135,000 · Balance 135,000 F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 7, 2026 20:12 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Disposition to issuerCommon Shares | 17,948 | $5.00 | $89,740.00 |
DisclosureSEC source: 0001447028-26-000061 · wk-form4_1791403925.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,328 F1 · shares: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,800 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · derivative · entry 5 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 78,800 shares Expires 2036-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,533 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · derivative · entry 4 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,067 Underlying: Common Shares · 52,533 shares Expires 2035-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the March 18, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Tax withholdingCommon Shares | 99,057 | $5.07 | $502,218.99 |
DisclosureSEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 3 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,276 F1 · kind: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 99,057 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 78,800 | $4.24 | $334,112.00 |
DisclosureSEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 2 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2026 Filed Sep 24, 2026 00:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 52,533 | $3.20 | $168,105.60 |
DisclosureSEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 78,800 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001447028-26-000039 · wk-form4_1781121921.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,800 Underlying: Common Shares · 78,800 shares Expires 2036-06-08 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 20:10 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 157,600 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001447028-25-000075 · wk-form4_1742501408.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,600 Underlying: Common Shares · 157,600 shares Expires 2035-03-18 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| February 25, 2023 Filed Mar 1, 2023 00:06 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-23-006475 · doc4.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-22-036697 · doc4.xml · derivative · entry 2 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,651 Underlying: Common Stock · 10,000 shares Expires 2022-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionCommon Stock | 10,000 | $1.07 | $10,700.00 |
DisclosureSEC source: 0000899243-22-036697 · doc4.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:10 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-22-030911 · doc4.xml · derivative · entry 2 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,651 Underlying: Common Stock · 10,000 shares Expires 2022-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:10 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionCommon Stock | 10,000 | $1.07 | $10,700.00 |
DisclosureSEC source: 0000899243-22-030911 · doc4.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:06 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-008585 · doc4.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:30 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-21-049011 · doc4.xml · derivative · entry 2 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,651 Underlying: Common Stock · 20,000 shares Expires 2022-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 23:30 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | Exercise / conversionCommon Stock | 20,000 | $1.07 | $21,400.00 |
DisclosureSEC source: 0000899243-21-049011 · doc4.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0000899243-21-003611 · doc4.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 26, 2021. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 23:00 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 74,435 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0000899243-20-002866 · doc4.xml · derivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,435 Underlying: Common Stock · 74,435 shares Expires 2030-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 31, 2020. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:15 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | ConversionSeries C Preferred Stock · Derivative | 6,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 4 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,339 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:15 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | ConversionSeries B Preferred Stock · Derivative | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 3 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 395 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:15 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | ConversionSeries A Preferred Stock · Derivative | 68,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 2 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,627 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:15 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | ConversionCommon Stock | 15,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027114 · doc4.xml · nonDerivative · entry 1 Beardsley Robert A · CIK 0001310845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.